干擾素誘導蛋白44在系統性紅斑狼瘡發病中的作用研究進展_West China Medical Journal

Authors：

李敏 , 楊南萍

Corresponding?author：

Keywords：

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李敏,楊南萍. 干擾素誘導蛋白44在系統性紅斑狼瘡發病中的作用研究進展. West China Medical Journal, 2009, 24(3): 789-791. doi: Copy

1.	SULLIVAN KE. Genetics of systemic lupus erythematosus.Clinical implications[J].Rheum Dis Clin North Am,2000,26（2）:229-256..
2.	黃向陽,顧越英,鮑春德,等.系統性紅斑狼瘡相關新基因IFIT4的亞細胞定位及IFNα對其表達的影響[J].中華風濕病學雜志,2006,10（4）:197-201..
3.	DARVASI A.Genomics: Gene expression meets genetics[J]. Nature,2003,422（6929）:269-270..
4.	HUA J, KIROU K, LEE C, et al. Functional assay of type Ⅰ interferon in systemic lupus erythematosus plasma and association with AntiRNA binding protein autoantibodies[J].Arthritis Rheum,2006,54（6）:1906-1916..
5.	WILSON L E, WIDMAN D, DIKMAN SH, et al. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection[J].Semin Arthritis Rheum,2002,32（6）: 163-173..
6.	LAI KC, CHANG KW, LIU CJ,et al. IFNinduced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma[J].Mol Cancer Res, 2008,6（9）: 1431-1439..
7.	KAWAMOTO M, HARIGAI M, HARA M, et al. Expression and function of inducible costimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferonγ and antidoublestranded DNA antibody production[J].Arthritis Res Ther,2006,8（3）:R62..
8.	HUANG X Y, GU Y Y, SHEN N. Interferoninduced protein with tetratricopeptide repeats 4 （IFIT4） is associated with systemic lupus erythematosus and promotes monocyte differentiation towards DClike cell[J].Arthritis Res Ther,2008,10（4）:R91..
9.	RNNBLOM L, GUNNAR VA. An etiopathogenic role for the type I IFN system in SLE[J].Trends Immunol, 2001,22（10）:323-329.
10.	HUANG X Y, YANG N P, OU X M. Sequential activation of protein kinase C δ and JNK is required for interferonαinduced expression of IFIT4[J].Cell Signal,2008,20（1）: 112-119..
11.	BAVE U, AIM GV, RONNBLOM L. The combination of apoptotic U937 cells and lupus IgG is a potent IFNα inducer[J]. J Immunol,2000, 165（6）: 3519-3526..
12.	LIN E, HWANG Y, CHEN EY. Genegene and geneenvironment interactions in interferon therapy for chronic hepatitis C[J].Pharmacogenomics,2007, 8（10）:1327-1335..
13.	AKATSUKA T, KOBAYASHI N, ISHIKAWA T, et al. Autoantibody response to microsomal epoxide hydrolase in hepatitis C and A[J].J Autoimmunity,2007, 28（1）:7-18..
14.	GEISS GK, CARTER VS, HE Y, et al. Gene expression profiling of the cellular transcriptional network regulated by α/β interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein[J].J Virol,2003,77（11）:6367-6375..
15.	HALLEN LC,BURKI Y,EBELING M, et al. Antiproliferative activity of the human IFNαinducible protein IFI44[J]. J Interferon Cytokine Res,2007,27（8）:675-680..
16.	PASIEKA T J, BAAS T, CARTER V S, et al. Functional genomic analysis of herpes simplex virus type 1 counteraction of the host innate response[J].J Virol,2006,80（15）:76007612..
17.	LOO Y M, GALE M J R. Viral regulation and evasion of the host response[J].Curr Top Microbiol Immunol,2007,316:295-313..
18.	INAMURA K, MATSUZAKI Y, UEMATSU N, et al. Rapid inhibition of MAPK signaling and antiproliferation effect via JAK/STAT signaling by interferonα in hepatocellular carcinoma cell lines[J].Biochimica et Biophysica Acta,2005,1745（3）:401-410..
19.	CRITCHLEYTHORNE R J, YAN N, NACU S, et al. Downregulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma[J].PLoS Medicine / Public Library of Science,2007,4（5）:0897-0911..
20.	HANS C P, KATHY M, TAKU O, et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD1 and CTLA4[J].Nat Imnmunol,2005,6（3）:280-286..
21.	INGLEFIELD J R, DUMITRU C D, ALKAN S S, et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN[J].J Interferon Cytokine Res,2008,28（4）:253-263..
22.	NICOLETTI F, DI MARCO R, PATTI F. et al. Shortterm treatment of relapsing remitting multiple sclerosis patients with interferon （IFN）β 1B transiently increases the blood levels of interleukin （IL）6, IL10 and IFNγ without significantly modifying those of IL-1β, IL-2, IL-4 and tumour necrosis factorα[J].Cytokine,2000,12（6）:682-687..
23.	PALUCKA A K, BLANCK J P, BENNETT L, et al. Crossregulation of TNF and IFN2-α in autoimmune diseases[J].Proc Natl Acad Sci USA,2005,（102）:3372-3377..
24.	NZEUSSEU TOUKAP A, GALANT C, THEATE I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus[J].Arthritis Rheum,2007,56（5）:1579-1588..

1. SULLIVAN KE. Genetics of systemic lupus erythematosus.Clinical implications[J].Rheum Dis Clin North Am,2000,26（2）:229-256..
2. 黃向陽,顧越英,鮑春德,等.系統性紅斑狼瘡相關新基因IFIT4的亞細胞定位及IFNα對其表達的影響[J].中華風濕病學雜志,2006,10（4）:197-201..
3. DARVASI A.Genomics: Gene expression meets genetics[J]. Nature,2003,422（6929）:269-270..
4. HUA J, KIROU K, LEE C, et al. Functional assay of type Ⅰ interferon in systemic lupus erythematosus plasma and association with AntiRNA binding protein autoantibodies[J].Arthritis Rheum,2006,54（6）:1906-1916..
5. WILSON L E, WIDMAN D, DIKMAN SH, et al. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection[J].Semin Arthritis Rheum,2002,32（6）: 163-173..
6. LAI KC, CHANG KW, LIU CJ,et al. IFNinduced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma[J].Mol Cancer Res, 2008,6（9）: 1431-1439..
7. KAWAMOTO M, HARIGAI M, HARA M, et al. Expression and function of inducible costimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferonγ and antidoublestranded DNA antibody production[J].Arthritis Res Ther,2006,8（3）:R62..
8. HUANG X Y, GU Y Y, SHEN N. Interferoninduced protein with tetratricopeptide repeats 4 （IFIT4） is associated with systemic lupus erythematosus and promotes monocyte differentiation towards DClike cell[J].Arthritis Res Ther,2008,10（4）:R91..
9. RNNBLOM L, GUNNAR VA. An etiopathogenic role for the type I IFN system in SLE[J].Trends Immunol, 2001,22（10）:323-329.
10. HUANG X Y, YANG N P, OU X M. Sequential activation of protein kinase C δ and JNK is required for interferonαinduced expression of IFIT4[J].Cell Signal,2008,20（1）: 112-119..
11. BAVE U, AIM GV, RONNBLOM L. The combination of apoptotic U937 cells and lupus IgG is a potent IFNα inducer[J]. J Immunol,2000, 165（6）: 3519-3526..
12. LIN E, HWANG Y, CHEN EY. Genegene and geneenvironment interactions in interferon therapy for chronic hepatitis C[J].Pharmacogenomics,2007, 8（10）:1327-1335..
13. AKATSUKA T, KOBAYASHI N, ISHIKAWA T, et al. Autoantibody response to microsomal epoxide hydrolase in hepatitis C and A[J].J Autoimmunity,2007, 28（1）:7-18..
14. GEISS GK, CARTER VS, HE Y, et al. Gene expression profiling of the cellular transcriptional network regulated by α/β interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein[J].J Virol,2003,77（11）:6367-6375..
15. HALLEN LC,BURKI Y,EBELING M, et al. Antiproliferative activity of the human IFNαinducible protein IFI44[J]. J Interferon Cytokine Res,2007,27（8）:675-680..
16. PASIEKA T J, BAAS T, CARTER V S, et al. Functional genomic analysis of herpes simplex virus type 1 counteraction of the host innate response[J].J Virol,2006,80（15）:76007612..
17. LOO Y M, GALE M J R. Viral regulation and evasion of the host response[J].Curr Top Microbiol Immunol,2007,316:295-313..
18. INAMURA K, MATSUZAKI Y, UEMATSU N, et al. Rapid inhibition of MAPK signaling and antiproliferation effect via JAK/STAT signaling by interferonα in hepatocellular carcinoma cell lines[J].Biochimica et Biophysica Acta,2005,1745（3）:401-410..
19. CRITCHLEYTHORNE R J, YAN N, NACU S, et al. Downregulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma[J].PLoS Medicine / Public Library of Science,2007,4（5）:0897-0911..
20. HANS C P, KATHY M, TAKU O, et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD1 and CTLA4[J].Nat Imnmunol,2005,6（3）:280-286..
21. INGLEFIELD J R, DUMITRU C D, ALKAN S S, et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN[J].J Interferon Cytokine Res,2008,28（4）:253-263..
22. NICOLETTI F, DI MARCO R, PATTI F. et al. Shortterm treatment of relapsing remitting multiple sclerosis patients with interferon （IFN）β 1B transiently increases the blood levels of interleukin （IL）6, IL10 and IFNγ without significantly modifying those of IL-1β, IL-2, IL-4 and tumour necrosis factorα[J].Cytokine,2000,12（6）:682-687..
23. PALUCKA A K, BLANCK J P, BENNETT L, et al. Crossregulation of TNF and IFN2-α in autoimmune diseases[J].Proc Natl Acad Sci USA,2005,（102）:3372-3377..
24. NZEUSSEU TOUKAP A, GALANT C, THEATE I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus[J].Arthritis Rheum,2007,56（5）:1579-1588..

West China Medical Journal

干擾素誘導蛋白44在系統性紅斑狼瘡發病中的作用研究進展

Abstract Full text Figures/Tables Video References Cited by

Format

Content